Solid tumor immunotherapy with T cell engager-armed oncolytic viruses

Solid tumor immunotherapy with T cell engager-armed oncolytic viruses

Oncolytic viruses (OVs) are novel anticancer agents that combine direct cancer cell killing with the stimulation of antitumor immunity. In addition, OVs can be engineered to deliver biological therapeutics directly to tumors, offering unique opportunities to design multimodal anticancer strategies....

Full description

Bibliographic Details
Main Authors:	Scott, E, Duffy, M, Freedman, J, Fisher, K, Seymour, L
Format:	Journal article
Published:	Wiley 2017

Similar Items

Arming oncolytic viruses with bispecific T cell engagers (BiTEs) for expression and secretion into the tumour microenvironment
by: Freedman, J
Published: (2017)

An oncolytic virus expressing a T-cell engager simultaneously targets cancer and immunosuppressive stromal cells
by: Freedman, J, et al.
Published: (2018)

Bi- and Tri-Specific T Cell Engager-Armed Oncolytic Viruses: Next-Generation Cancer Immunotherapy
by: Zong Sheng Guo, et al.
Published: (2020-07-01)

Combination Immunotherapy Using Oncolytic Virus for the Treatment of Advanced Solid Tumors
by: Chang-Myung Oh, et al.
Published: (2020-10-01)

Oncolytic Virus Immunotherapy
by: Antonio Marchini, et al.
Published: (2021-07-01)

Measles Virus as an Oncolytic Immunotherapy
by: Christine E. Engeland, et al.
Published: (2021-02-01)

Oncolytic Viruses: Immunotherapy Drugs for Gastrointestinal Malignant Tumors
by: Qingbo Li, et al.
Published: (2022-06-01)

Immunotherapy by mesenchymal stromal cell delivery of oncolytic viruses for treating metastatic tumors
by: A-Rum Yoon, et al.
Published: (2022-06-01)

Fusogenic Viruses in Oncolytic Immunotherapy
by: Teresa Krabbe, et al.
Published: (2018-06-01)

Oncolytic viruses for cancer immunotherapy
by: Otto Hemminki, et al.
Published: (2020-06-01)

Oncolytic virus immunotherapy: future prospects for oncology
by: Junaid Raja, et al.
Published: (2018-12-01)

Oncolytic adenovirus expressing bispecific antibody targets T‐cell cytotoxicity in cancer biopsies
by: Freedman, J, et al.
Published: (2017)

Oncolytic vaccinia virus and cancer immunotherapy
by: Lihua Xu, et al.
Published: (2024-01-01)

Oncolytic herpes simplex virus and immunotherapy
by: Wenqing Ma, et al.
Published: (2018-12-01)

Updates on Oncolytic Virus Immunotherapy for Cancers
by: Cole Peters, et al.
Published: (2019-03-01)

Perspectives on immunotherapy via oncolytic viruses
by: Alberto Reale, et al.
Published: (2019-02-01)

Tackling HLA Deficiencies Head on with Oncolytic Viruses
by: Kerry Fisher, et al.
Published: (2021-02-01)

CAR-T Cells and Oncolytic Viruses: Joining Forces to Overcome the Solid Tumor Challenge
by: Sonia Guedan, et al.
Published: (2018-10-01)

Oncolytic vaccinia virus expressing a bispecific T-cell engager enhances immune responses in EpCAM positive solid tumors
by: Min Wei, et al.
Published: (2022-11-01)

Replication and Spread of Oncolytic Herpes Simplex Virus in Solid Tumors
by: Bangxing Hong, et al.
Published: (2022-01-01)

Counteracting Immunosuppression in the Tumor Microenvironment by Oncolytic Newcastle Disease Virus and Cellular Immunotherapy
by: Volker Schirrmacher, et al.
Published: (2022-10-01)

Oncolytic Viruses: Newest Frontier for Cancer Immunotherapy
by: Masmudur M. Rahman, et al.
Published: (2021-10-01)

The Evolution and Future of Targeted Cancer Therapy: From Nanoparticles, Oncolytic Viruses, and Oncolytic Bacteria to the Treatment of Solid Tumors
by: Kyle M. Pierce, et al.
Published: (2021-11-01)

Claudin18.2 bispecific T cell engager armed oncolytic virus enhances antitumor effects against pancreatic cancer
by: Shiyu Liu, et al.
Published: (2023-09-01)

Comparison of Clinically Relevant Oncolytic Virus Platforms for Enhancing T Cell Therapy of Solid Tumors
by: Victor Cervera-Carrascon, et al.
Published: (2020-06-01)

Intravesical immunotherapy with a GM-CSF armed oncolytic vesicular stomatitis virus improves outcome in bladder cancer
by: Coby Rangsitratkul, et al.
Published: (2022-03-01)

Tune Up In Situ Autovaccination against Solid Tumors with Oncolytic Viruses
by: Teresa Nguyen, et al.
Published: (2018-05-01)

CD8+ T-cell Immune Evasion Enables Oncolytic Virus Immunotherapy
by: Aldo Pourchet, et al.
Published: (2016-03-01)

Heating it up: Oncolytic viruses make tumors ‘hot’ and suitable for checkpoint blockade immunotherapies
by: Shashi Gujar, et al.
Published: (2018-08-01)

Oncolytic Virus Engineering and Utilizations: Cancer Immunotherapy Perspective
by: Palaniyandi Muthukutty, et al.
Published: (2023-07-01)

Comprehensive assessment on the applications of oncolytic viruses for cancer immunotherapy
by: Richard Kolade Omole, et al.
Published: (2022-12-01)

Engineering strategies to enhance oncolytic viruses in cancer immunotherapy
by: Yaomei Tian, et al.
Published: (2022-04-01)

Oncolytic virus driven T-cell-based combination immunotherapy platform for colorectal cancer
by: Mathieu J. F. Crupi, et al.
Published: (2022-11-01)

Tumor Restrictions to Oncolytic Virus
by: Markus Vähä-Koskela, et al.
Published: (2014-04-01)

Oncolytic virotherapy evolved into the fourth generation as tumor immunotherapy
by: Xianwang Wang, et al.
Published: (2023-07-01)

Combination of IAP Antagonists and TNF-α-Armed Oncolytic Viruses Induce Tumor Vascular Shutdown and Tumor Regression
by: Shawn T. Beug, et al.
Published: (2018-09-01)

Big Data Offers Novel Insights for Oncolytic Virus Immunotherapy
by: Stephanie L. Swift, et al.
Published: (2016-02-01)

Oncolytic virus immunotherapy induces immunogenic cell death and overcomes STING deficiency in melanoma
by: Praveen K. Bommareddy, et al.
Published: (2019-07-01)

Oncolytic adenovirus expressing bispecific antibody targets T‐cell cytotoxicity in cancer biopsies
by: Joshua D Freedman, et al.
Published: (2017-08-01)

Preclinical evaluation of engineered oncolytic herpes simplex virus for the treatment of pediatric solid tumors.
by: Michael L Megison, et al.
Published: (2014-01-01)